Regiospecific Synthesis of 1,4,5-Trisubstituted 1,2,3-Triazoles via Enolate–Azide Cycloaddition between 1,3-Dicarbonyl Compounds and Aryl Azides

Synthesis and biological evaluation of ciprofloxacin - 1,2,3-triazole hybrids as antitumor, antibacterial, and antioxidant agents

Six novel ciprofloxacin-1,2,3-triazole hybrids (6a-f) were synthesized via click reaction, by reacting of methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(3-oxobutanoyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate (5) with various aryl azides (9a-f). The new compounds were characterized using High-Resolution Mass Spectrometry (HRMS), 1H NMR, 13C NMR, and elemental analysis. Compounds (6a-f) screened for their in vitro anticancer activity against three cell lines, namely, non-small cell lung cancer (A549), glioblastoma (U-87 MG), and breast cancer (MCF7). Hybrids 6a and 6b exhibited remarkable anti-proliferative activity against all three cell-lines. IC50 values of 6b for all cancer cell lines were significantly lower comparing to the standard reference compound IC50. The IC50 of 6b for the normal cell (HDF) line was significantly higher than the reported for cisplatin [IC50 = 170.7 ± 8.1 μM/ml (HDF), (p ≤ 0.001)], indicating less toxicity towards normal cells and thereby has a better therapeutic index, with a selectivity index of 142.3 for U87 cell line. Compounds 6e, 6d, and 6f displayed significant cytotoxic activity against only U-87 and MCF-7 cancer cell lines, compared to normal cells (HDF). Compound 6f [IC50 = 7.9 ± 2.3 μM/ml (U-87) and 10.6 ± 3 μM/ml (MCF-7)] was more potent than cisplatin [IC50 = 28.3 ± 5.3 μM/ml (U-87) and 26.9 ± 4.7 μM/ml (MCF-7)] in displaying anti-proliferative effect against U-87 and MCF-7 cells, with less cytotoxic to normal cells [IC50 = 141.7 ± 4.1] than cisplatin [IC50 = 40.9 ± 5.4]. Moreover, they were tested for their antioxidant activity in DPPH and ABTS assays and antibacterial activity.

Ligand influence in electrocatalytic properties of Cu(II) triazole complexes for hydrogen peroxide detection in aqueous media

In this work, electrocatalytic changes of Cu(II) triazole complexes (Cu(L)₂) resulting from inductive effects were evaluated to fabricate a sensor for hydrogen peroxide (H₂O₂) determination. Three copper(II) complexes with electronically differentiated ligands were synthesized by slow diffusion method and characterized by X-ray crystallography, Fourier transformed infrared (FTIR), UV-Vis, scanning electron microscopy (SEM) and voltammetry cyclic (CV). Cu(LOMe)2/GC, Cu(LBr)2/GC and Cu(LNO2)2/GC sensors were then prepared. Under optimal conditions (pH = 11), the optimal sensor presented a response at -0.5 V, good linear range of 1-32 μM, reproducibility (1.7%), repeatability (1.2%), LOD of 0.0246 μM (S/N = 5), LOQ of 0.0747 μM (S/N = 5) and selectivity. Additionally, Cu(LNO2)2/GC sensor has been successfully applied in commercial substances, such as mouthwash, milk and tea.

Self-Cognizant Bionic Liquid Sensor for Pathogen Diagnosis

As observed in the outbreaks of SARS and swine flu, as well as many other infectious diseases, the huge volume of human traffic across numerous enclosed public venues has posed immense challenges to preventing the spread of communicable diseases. There is an urgent need for effective disease surveillance management in public areas under pandemic outbreaks. The physicochemical properties associated with ionic liquids make them particularly suited for molecular communications in sensing networks where low throughput is quite adequate for pathogen detection. This paper presents a self-cognizant system for rapid diagnosis of infectious disease using a bionic sensor such that testing can be supported without collecting a fluid sample from a subject through any invasive methods. The system is implemented for testing the performance of the proposed bionic liquid sensing network.

Crystal structure of ethyl 1-(3,4-dimethylphenyl)-5-methyl-1H-1,2,3-triazole-4-carboxylate, C14H17N3O2

C14H17N3O2, monoclinic, P21/c (no. 14), a = 14.9289(7) Å, b = 7.8070(4) Å, c = 12.4664(7) Å, β = 106.821(4)°, V = 1390.79(13) Å3, Z = 4, R gt(F) = 0.0646, wR ref(F 2) = 0.1682, T = 293(2) K.

Crystal structure of ethyl 5-methyl-1-(pyridin-3-yl)-1H-1,2,3-triazole-4-carboxylate, C11H12N4O2

C11H12N4O2, monoclinic, P21/c (no. 14), a = 12.0258(15) Å, b = 8.0563(10) Å, c = 12.4478(13) Å, β = 104.157(4)°, V = 1169.4(2) Å3, Z = 4, Rgt(F) = 0.0619, wRref(F2) = 0.1616, T = 293(2) K.

Crystal structure of ethyl 1-(4-chlorophenyl)-5-methyl-1H-1,2,3-triazole-4 carboxylate, C12H12ClN3O2

C12H12ClN3O2, monoclinic, P21/c (no. 14), a = 13.5673(5) Å, b = 7.7549(3) Å, c = 12.4911(5) Å, β = 102.468(2)°, V = 1283.23(9) Å3, Z = 4, Rgt (F) = 0.047, wRref (F 2) = 0.123, T = 293(2) K.